Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sierra Oncology Inc (SRRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks

Stock Research Monitor: SRRA, ONCE, and SPPI

SRNE : 7.85 (-1.26%)
ONCE : 78.39 (-0.80%)
SRRA : 2.40 (+3.45%)
Sierra Oncology Reports First Quarter Results

- SRA737 Monotherapy Phase 1/2 trial expanded to enroll CCNE1 -driven ovarian cancer cohort - - SRA737 Low-Dose Gemcitabine Combination Phase 1/2 trial advanced into cohort expansion phase - ...

SRRA : 2.40 (+3.45%)
Sierra Oncology Reports First Quarter Results

SRA737 Monotherapy Phase 1/2 trial expanded to enroll CCNE1-driven ovarian cancer cohort - - SRA737 Low-Dose Gemcitabine Combination Phase 1/2 trial advanced into cohort expansion phase - - $133.8 million...

SRRA : 2.40 (+3.45%)
Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

- Two posters reporting activity for SRA737 with PARPi (in CCNE1 -driven cancers, HRR proficient cancers, and PARPi-resistant cancers) reinforce the potential broad clinical utility of this combination...

SRRA : 2.40 (+3.45%)
Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

SRRA : 2.40 (+3.45%)
Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

- Presentation scheduled for 3:00 p.m. ET on March 23, 2018 -

SRRA : 2.40 (+3.45%)
Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

SRRA : 2.40 (+3.45%)
Pre-Market Technical Scan on Biotech Equities -- Riot Blockchain, Sage Therapeutics, Sarepta Therapeutics, and Sierra Oncology

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on RIOT, SAGE, SRPT, and SRRA which can be accessed for free by signing up to www.wallstequities.com/registration....

SRPT : 91.65 (+1.84%)
SRRA : 2.40 (+3.45%)
RIOT : 7.59 (-2.57%)
SAGE : 155.33 (-1.80%)
Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

SRRA : 2.40 (+3.45%)
Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

VANCOUVER , March 14, 2018 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics...

SRRA : 2.40 (+3.45%)
Sierra Oncology Announces Pricing of Public Offering of Common Stock

VANCOUVER , March 2, 2018 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage...

SRRA : 2.40 (+3.45%)
Sierra Oncology Announces Pricing of Public Offering of Common Stock

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced...

SRRA : 2.40 (+3.45%)
Sierra Oncology Announces Proposed Public Offering of Common Stock

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced...

SRRA : 2.40 (+3.45%)
Sierra Oncology Significantly Expands Clinical Development Program

Ongoing SRA737 clinical studies expanded to target aggregate enrollment of 200 patients across ten cancer indications -- Adding new SRA737 monotherapy cohort for CCNE1-driven ovarian cancer -- SRA141 IND...

SRRA : 2.40 (+3.45%)
Sierra Oncology Significantly Expands Clinical Development Program

- Ongoing SRA737 clinical studies expanded to target aggregate enrollment of 200 patients across ten cancer indications – - Adding new SRA737 monotherapy cohort for CCNE1 -driven ovarian cancer...

SRRA : 2.40 (+3.45%)
Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study

Janssen to supply PARP inhibitor niraparib for Sierra's Phase 1b/2 combination trial with Chk1 inhibitor SRA737 -

SRRA : 2.40 (+3.45%)
Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual Meeting

- Data reinforce the potential clinical utility of combination therapy -

SRRA : 2.40 (+3.45%)
Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual Meeting

Data reinforce the potential clinical utility of combination therapy -

SRRA : 2.40 (+3.45%)
Stock Review for Biotech's Investors -- Sage Therapeutics, Sarepta Therapeutics, Sierra Oncology, and Sorrento Therapeutics

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on SAGE, SRPT, SRRA, and SRNE which can be accessed for free by signing up to www.wallstequities.com/registration....

SRNE : 7.85 (-1.26%)
SRPT : 91.65 (+1.84%)
SRRA : 2.40 (+3.45%)
SAGE : 155.33 (-1.80%)
Sierra Oncology to host Program Update in New York on February 27th

Sierra also to present at the BIO CEO & Investor Conference in New York on February 12th -

SRRA : 2.40 (+3.45%)

Van Meerten Stock Picks

5 Great Growth Stocks
This morning I wanted to find 5 stocks that were predicted to have double digit growth in both Revenue and Earnings over the next 5 years that were also having great current performance.
LULU -0.23 , ABMD -0.18 , AAXN +0.93 , NSP -0.05 , ERI +0.50
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures ended the Friday session with gains of 1 to 2 3/4 cents in the front months. July was up 3 1/2 cents on the week. CFTC data showed speculators adding 8,298 contracts to their net long position in corn futures and options to 199,970 in th...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar